Aya Jakobovits

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA.

Agensys, Inc. develops a pipeline of therapeutic fully human monoclonal atibodies (mAbs) to treat cancer. It develops a pipeline of naked and antibody-drug conjugated (ADC) therapeutic antibodies to treat cancer indications, including prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin. The company was founded in 1997 and is headquartered in Santa Monica, CA.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Alliance for Cancer Gene Therapy, Inc. provides funding for cancer research. The non-profit company is based in Stamford, CT. The company was founded by Edward Netter. Kevin Honeycutt has been the CEO of the company since 2018.

Yeda Research & Development Co. Ltd. engages in development of natural science and services. It covers broad of spectrum including: biotechnology, pharmaceuticals and diagnostics, bioinformatics, proteomics, biomatics and system biology, medical devices, renewable energy, bio fuels, clean technology and environmental sciences, agricultural and plants genetics, chemistry and nanotechnology, physics and electro-optics, mathematics and computer science. The company is headquartered in Rehovot, Israel.

Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA.

cCAM Biotherapeutics Ltd. is a preclinical-stage company engaging in the development of immunotherapies to treat cancer. The company was founded by Silvia Noiman and Gal Markel in 2010 and is headquartered in Hod Ha'Sharon, Israel.